News

The features of pediatric IBD can be non-specific, but there are signs in biopsies and clinical history that may indicate what is and isn't IBD.

José López, MD, discusses the results of a study he led examining contemporary trends in racial disparities as it pertains to LVAD utilization in patients with heart failure with reduced ejection fraction.

An analysis of age-stratified fatty liver disease patient demographics show a surprising shift in racial/ethnic and sex trends among children and adolescents.

Lauren Eyadiel, MMS, PA-C, offers insight into a presentation from HFSA 2023 examining strategies for overcoming financial barriers to GDMT optimization in heart failure.

Major advances to biomarkers, targeted therapies and a modernized care team could help IBD specialists achieve a more nuanced care strategy for children.

Though a regimen of steroids and immunosuppressants are well proven, alternative options may be necessary.

New results from the AiDAPT trial show hybrid closed-loop therapy significantly improves maternal glycemic control during pregnancy complicated by T1D.

New research suggests multiple antibiotic courses may influence levels of the protein zonulin—which in part may indicate a higher risk of celiac disease.

Muthiah Vaduganathan, MD, MPH, offers insight and perspective into a new annual report from the Heart Failure Society of America outlining trends in epidemiology and outcomes in heart failure.

In our September 2023 cardiology month in review, the editorial team of HCPLive Cardiology highlights a trio of regulatory decision from the FDA and a group of 5 different articles spotlighting data from phase 2 or phase 3 trials.

Obesity rates in the US have skyrocketed, and so has the prevalence of several comorbid gastrointestinal and hepatic diseases - not all patients know their risks or have the financial means to take preventative measures.

This new research could allow for limitations related to safety that could promote mitigation of ambient air pollution and protect those with allergies.

GLP-1 agonists for weight loss increased the risk of pancreatitis, gastroparesis, and bowel obstruction compared with the use of bupropion-naltrexone.

This announcement by Arcutis broadens the psoriasis drug’s indication and was done to help simplify management of the skin condition for younger patients as well.

Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.

This new data may help clinicians not to over-treat or over-medicalize with infants that have a SARS-CoV-2 infection.

An interview regarding the current impacts of environmental health on food availability, nutrition, and more.

An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.

Stephen Greene, MD, discusses trials, data, and themes to look for at the HFSA 2023 meeting.

The latest episode of our mini-docuseries focuses on disparities in ophthalmology, from preventable vision impairment to gaps in access in underserved communities.

A new study seeks to compare the outcomes of biopsies among American children at risk of celiac disease, with European thresholds that would deem such biopsies unnecessary.

This new analysis was described as the first estimate on the prevalence in Europe of specific TNA and sensitization.

Findings from the pivotal phase 3 trial that which supported linaclotide's FDA approval show significant benefit in bowel movement and stool consistency.

Our ophthalmology month in review for September 2023 highlights our top stories in retina, the latest news from the FDA, and insights into the evolving specialty landscape.

The author of the largest clinical trial for pediatric PFIC to date discusses the various benefit maralixibat provides to disease managementr.

A new review and analysis suggests a combination treatment regimen for children in acute liver failure due to autoimmune hepatitis may help them maintain native liver survival.

Pooled phase 3 data presented at NASPGHAN 2023 support the benefit-risk profile of the IBAT inhibtor in treating the rare liver disease.

Results demonstrated comparable safety, immunogenicity, and pharmacokinetics between adalimumab-afzb and the reference product.